Suggestions
Chad Moles
Chief Science Officer & Co-founder, Humane Genomics Inc.
Professional Background
Chad Moles is an accomplished biotechnology professional and the Chief Scientific Officer (CSO) as well as a co-founder of Humane Genomics, a pioneering startup at the forefront of developing synthetic viruses aimed at precision cancer therapies. With a strong commitment to harnessing the power of biotechnology, Chad has dedicated his career to exploring innovative solutions for complex medical challenges, particularly in the field of oncology. His extensive experience in research and development, combined with his entrepreneurial spirit, positions him as a vital contributor to advancing cancer treatment methodologies.
Humane Genomics is known for its groundbreaking approach in utilizing synthetic viruses, enabling more targeted and effective cancer therapies. Under Chad’s leadership, the company is making significant strides in transforming the landscape of cancer treatment, demonstrating a commitment to improving patient outcomes through innovative scientific approaches. Chad's expertise in biotechnology not only drives the vision of Humane Genomics but also inspires a culture of excellence and innovation in the biotech community.
Education and Achievements
Chad Moles pursued his advanced studies by earning a Master’s Degree in Biotechnology from the prestigious Columbia University in the City of New York. This rigorous program equipped him with the critical skills and knowledge necessary to excel in the biotechnology sector. Prior to this, Chad earned his Bachelor’s Degree in Public Health from Tulane University, where he developed a strong foundation in health sciences and an understanding of public health implications in biotechnology.
His educational journey laid the groundwork for a successful career in research and development roles within various esteemed institutions. Notably, he has held several positions that reflect both his passion for scientific inquiry and his commitment to advancing knowledge in biotechnology. As a former Graduate Student at NYU Langone Medical Center, Chad contributed valuable insights into molecular biology and its applications in medicine. His work at Columbia Technology Ventures as a Graduate Student further enriched his understanding of the commercialization of biotechnological innovations, proving essential in his entrepreneurial role at Humane Genomics.
Chad's early career included impactful internships and research experiences, such as his time as an Intern at Neochromosome, Inc., where he focused on the emerging field of synthetic biology. His role as a Post-baccalaureate Research Fellow at Baylor College of Medicine exemplifies his dedication to rigorous scientific research, allowing him to collaborate on various projects aimed at understanding and combating diseases. Additionally, his undergraduate research experiences at Cincinnati Children's Hospital Medical Center and Universidad Autónoma de Yucatán provided him with a solid foundation in clinical research methodologies and data analysis.
Achievements
Throughout his career, Chad Moles has achieved significant milestones that showcase his expertise in the biotechnology field and his commitment to advancing cancer therapies. His role as CSO and co-founder at Humane Genomics highlights his leadership skills and visionary capabilities in shaping the future of precision medicine. The company’s innovative approach to utilizing synthetic viruses marks a pivotal moment in cancer treatment, positioning it as a vital player in the biotech industry.
Chad has been actively involved in several research projects that have ranged from cancer biology to synthetic biology applications. His work has garnered interest in the scientific community, and he has participated in various conferences and symposia to share his findings and insights. His collaborative spirit and commitment to fostering partnerships within the research community enhance the scope of his work and its impact on public health.
Chad Moles’ career reflects a passion for science, innovation, and a deep commitment to improving health outcomes through biotechnology. His educational background, combined with extensive research experience, underscores his position as a thought leader in the industry. As he continues to push the boundaries of what is possible within biotech, his journey serves as an inspiration for students and aspiring scientists in the field.
